January 14, 2015
The Patent Trial and Appeal Board on Tuesday rejected petitions challenging Jazz Pharmaceuticals Inc.'s patents for the narcolepsy drug Xyrem under the America Invents Act business method review program, ruling that the patents are not financial in nature, as required by the program. (Correction: An earlier story incorrectly stated that this decision was the first time the PTAB has ruled that a patent being challenged under the business review program was not related to financial services. The error has been corrected.)